Hints and tips:
Related Special Reports
...GIC took a 25 per cent stake in CitizenM five years ago in a deal that valued the business at €2bn including debt....
...A sharper focus on operations is a crucial part of efforts by activist investors to put the gambling group in a position where it could ultimately be sold or broken up....
...The bill labels Shanghai-based WuXi AppTec “a biotechnology company of concern”, which is described as any entity posing a risk to the US by engaging in joint research with a foreign adversary’s military...
...the sale if a buyer is found....
...A small number of people in equities are trialling a rival offering from US data and software company FactSet, which costs about a third of the price, one of the people said....
...The health insurer said it recorded a net loss of around $1.53 a share in the three months to the end of March, compared with a profit of $5.95 a share during the same period last year....
...Tirzepatide is part of a new class of weight-loss drugs, known as GLP-1s, which includes Novo Nordisk’s Wegovy and Ozempic drugs, that are projected to expand to a $100bn market by the end of the decade,...
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...The group had a market value of $600mn, as of market close on Friday....
...Joaquin Duato, J&J’s chief executive, said the acquisition “provides a unique opportunity to accelerate our impact in cardiovascular intervention”....
...Last year, Shockwave completed a $147mn acquisition of Neovasc, which produces a device to treat refractory angina, another type of heart defect....
...Aardvark Therapeutics, a US biotech group developing a weight loss pill, is planning to raise up to $200mn in an initial public offering as early as this summer, propelled by investor hype over anti-obesity...
...A person in Texas has contracted the second known human case of H5N1 bird flu in the US, the Centers for Disease Control and Prevention said....
...The conversion of BT Tower would mark the latest bid to transform a historic London building into a top-end hotel....
...Greencore did complete a £50mn share repurchase programme recently, but a person familiar with Oasis’s thinking described them as “really small”....
...It then established an outpost in 2014 in a cluster of renovated farm buildings in the rural English town of Bruton. The launch was a boon to property prices across the local Somerset area....
...’s chief medical officer, said in a statement....
...A deal combining Choice and its bigger rival, both of which operate under a franchised model, would have created one of the largest budget hotel owners in the US, with nearly 1.5mn rooms....
...A decision on Eli Lilly’s donanemab drug from the US Food and Drug Administration was originally due by the end of the first quarter, but the medicine will now be subject to a further review by an advisory...
...Orchard cited a review by the Institute for Clinical and Economic Review (ICER), a US non-profit that attempts to calculate a fair price for drugs, which concluded last year that Lenmeldy would be cost-effective...
...“It’s a huge potential clinical breakthrough and so I do think [sales growth is] going to be material”....
...The Boston-based company struck a deal with the Kenyan government a year ago to invest about $200mn in a facility that would produce up to 500mn vaccine shots a year....
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against US pharmacy chains such as CVS and Walgreens. Read more here...
...was a distant prospect....
International Edition